Vivienne Green
Corporate Officer/Principal chez Australian Psychological Society
Postes actifs de Vivienne Green
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Australian Psychological Society | Corporate Officer/Principal | - | - |
Historique de carrière de Vivienne Green
Anciens postes connus de Vivienne Green
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Responsable des Ressources Humaines | - | - |
| BIOTA HOLDINGS LTD. | Responsable des Ressources Humaines | 01/07/2011 | - |
Statistiques
Internationale
| Australie | 3 |
| Etats-Unis | 2 |
Opérationnelle
| Human Resources Officer | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
| Australian Psychological Society | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Bourse
- Insiders
- Vivienne Green
- Expérience
